Brokerage : Daishin Securities
Analyst : Kahye Hong (RA: Cherry Lee)
Investment Rating : Buy (Initiation)
Target Price : KRW 500,000 (Initiation)
Core Momentum : Clinically and commercially validated ALT-B4 platform drives ongoing big pharma licensing, while Keytruda SC commercialization secures long-term milestone/royalty cash flows alongside modality expansion into ADCs.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: Buy (Initiation) / 6-Month Target Price KRW 500,000 (Initiation) (Upside potential of 36.4% based on the May 19, 2026 closing price of KRW 366,500)
- Valuation Methodology: Derived via rNPV DCF model based on pipeline milestone and royalty projections (assumes existing contracts plus 2 new annual contracts with IV peak sales of USD 5B and conversion rates of 40%–60%; WACC 9.26%, terminal growth rate 4.5%. Potential target price upside if deal terms exceed baseline assumptions or commercialized asset ratios rise).
- Market Data: KOSPI Index 1,084.36pt / Market Cap KRW 19.64 Trillion (Weight 2.91%) / Capital Stock (Common) KRW 27.0 Billion / 52-Week High KRW 559,000, Low KRW 317,500 / 120-Day Average Trading Value KRW 242.4 Billion / Foreign Ownership 14.24% / Major Shareholders: Soonjae Park and 4 affiliates 20.33%, Inwoo Hyung and 2 affiliates 5.08%
- Annual Financial Forecast (Daishin Securities Estimates):
- 2026F: Revenue KRW 454.0 Billion, Operating Profit KRW 295.0 Billion (OPM 65.0%), Pre-tax Profit KRW 358.0 Billion, Net Profit (Controlling) KRW 270.0 Billion, EPS KRW 5,000, BPS KRW 12,878, PER 73.8x, PBR 28.7x, ROE 47.3%
- 2027F: Revenue KRW 513.0 Billion, Operating Profit KRW 344.0 Billion (OPM 67.1%), Pre-tax Profit KRW 408.0 Billion, Net Profit (Controlling) KRW 308.0 Billion, EPS KRW 5,700, BPS KRW 18,206, PER 64.7x, PBR 20.3x, ROE 36.7%
- 2028F: Revenue KRW 632.0 Billion, Operating Profit KRW 448.0 Billion (OPM 70.9%), Pre-tax Profit KRW 513.0 Billion, Net Profit (Controlling) KRW 387.0 Billion, EPS KRW 7,168, BPS KRW 25,006, PER 51.5x, PBR 14.8x, ROE 33.2%
🚀 2. [Market Opportunities & Business Outlook]
- Validated Platform & Expanding Global Partnerships:
- Regulatory approvals and commercial launch of Keytruda SC across the US and EU fully validate ALT-B4’s clinical and commercial viability.
- Partnering momentum continues with multiple global pharma leaders, reinforced by newly executed deals with Biogen and GSK in 2026.
- The structural industry shift from IV to SC administration—driven by patient convenience and healthcare cost savings—strengthens Alteogen’s negotiating leverage as its track record expands.
- Commercial Milestone Inflows & Long-Term Cash Flow Visibility:
- Rapid acceleration of sales-linked milestone receipts for Keytruda SC: estimated at ~KRW 300 Billion in 2026, ~KRW 400 Billion in 2027, and ~KRW 500 Billion in 2028, subsequently transitioning into recurring commercial royalties.
- Dupixent SC’s anticipated Phase 3 initiation within the year will add milestone visibility, supported by secured platform patent protection running through 2043.
- Re-Rating Drivers: New Deals & Next-Generation Modalities:
- Noise regarding royalty rates and patent litigation is gradually easing, removing major overhangs.
- Execution of additional out-licensing deals in Q2 2026 is expected to serve as a primary catalyst for potential valuation upgrades.
- Key H2 operational checkpoints: Dupixent SC Phase 3 start, Enhertu SC clinical readout, and Keytruda SC market share expansion. Specifically, as the industry’s first attempt to develop an SC formulation for an ADC, clinical success with Enhertu SC will demonstrate the platform’s scope expanding from standard antibodies into ADCs, with subsequent expansions into complex modalities like bispecifics offering medium-to-long-term valuation upside.
📝 Editor’s Comment (Perspective)
The analyst views Alteogen as a global subcutaneous drug delivery platform that has completed clinical validation through Keytruda SC’s US/EU rollouts and entered a phase of securing long-term cash flow visibility backed by Keytruda SC sales milestones and future royalties, initiating coverage with a BUY rating and a target price of KRW 500,000. The overarching perspective prioritizes the long-term cash flow visibility anchored by patent exclusivity through 2043 and the potential to expand the platform’s application to ADCs (via Enhertu SC) over transient patent litigation noise.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the actual receipt of ~KRW 300 Billion in Keytruda SC sales milestones in 2026, the terms and closure of new licensing deals in Q2 2026, the formal initiation of Dupixent SC Phase 3 trials in H2, and clinical trial results for Enhertu SC. These developments can be verified through upcoming quarterly earnings releases, official company IR presentations, and regulatory filings on DART/KRX.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
